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Abstract
Factor	XIII	deficiency	(FXIIID)	is	a	rare	hereditary	bleeding	disorder	arising	from	het-
erogeneous	mutations,	which	can	lead	to	life-	threatening	hemorrhage.	The	diagnosis	
of	FXIIID	is	challenging	due	to	normal	standard	coagulation	assays	requiring	specific	
FXIII	 assays	 for	diagnosis,	which	 is	 especially	 difficult	 in	developing	 countries.	 This	
report	presents	an	overview	of	FXIIID	diagnosis	and	laboratory	methods	and	suggests	
an	algorithm	to	improve	diagnostic	efficiency	and	prevent	missed	or	delayed	FXIIID	
diagnosis.	Assays	measuring	FXIII	activity:	The	currently	available	assays	utilized	 to	
diagnose	FXIIID,	including	an	overview	of	their	complexity,	reliability,	sensitivity,	and	
specificity,	 as	well	 as	mutational	 analysis	 are	 reviewed.	The	use	of	 a	FXIII	 inhibitor	
assay	is	described.	Diagnostic	tools	in	FXIIID:	Many	laboratories	are	not	equipped	with	
quantitative	FXIII	activity	assays,	and	if	available,	limitations	in	lower	activity	ranges	
are	important	to	consider.	Clot	solubility	tests	are	not	standardized,	have	a	low	sensi-
tivity,	and	are	therefore	not	recommended	as	routine	screening	test;	however,	they	
are	the	first	screening	test	in	almost	all	coagulation	laboratories	in	developing	coun-
tries.	To	minimize	the	number	of	patients	with	undiagnosed	FXIIID,	test	quality	should	
be	improved	in	less	well-	equipped	laboratories.	Common	country-	specific	mutations	
may	facilitate	diagnosis	through	targeted	genetic	analysis	in	reference	laboratories	in	
suspected	cases.	However,	genetic	analysis	may	not	be	feasible	in	every	country	and	
may	miss	spontaneous	mutations.	Centralized	FXIII	activity	measurements	should	also	
be	 considered.	An	 algorithm	 for	 diagnosis	 of	 FXIIID	 including	different	 approaches	
dependent	upon	laboratory	capability	is	proposed.
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1  | INTRODUCTION
Inherited	 factor	 XIII	 deficiency	 (FXIIID)	 is	 a	 rare	 bleeding	 disorder	
affecting	the	final	stage	of	the	coagulation	system	and	resulting	in	a	
bleeding	diathesis.1	The	worldwide	 incidence	of	FXIIID,	 inherited	as	
an	autosomal	recessive	disorder,	is	approximately	one	per	1-	3	million	
people.	Its	prevalence	depends	on	geographic	region	and	is	higher	in	
areas	in	which	consanguineous	marriage	is	common;	however,	there	is	
no	difference	worldwide	in	affected	ethnicity	or	race.	The	molecular	
defects	in	FXIIID	arise	from	heterogeneous	mutations,	which	can	be	
country-	specific,	 facilitating	methods	 to	 confirm	FXIIID	diagnosis	 in	
such	areas.2-4
Signs	 and	 symptoms	of	FXIIID	 range	 from	 life-	threatening	hem-
orrhage	such	as	intracranial	hemorrhage	to	mild	forms,	including	skin	
bleeding.	Umbilical	 cord	bleeding	and	soft	 tissue	hematoma	are	 the	
most	common	and	often	the	 first	symptom	of	FXIIID.3,5,6 In women 
with	 severe	FXIIID,	 recurrent	miscarriage	 is	 common.	Heterozygous	
carriers	may	show	a	bleeding	tendency	upon	provocation	such	as	trau-
matic	injury	or	invasive	procedures,	and	in	some	cases,	umbilical	cord	
bleeding,	menorrhagia,	miscarriages,	or	postpartum	bleeding.7-9
The	diagnosis	of	FXIIID	is	challenging	due	to	the	rarity	of	the	dis-
order	and	because	standard	coagulation	screening	tests,	including	pro-
thrombin	time,	activated	partial	thromboplastin	time,	thrombin	time,	
platelet	count,	or	bleeding	time,	are	normal;	 therefore,	specific	FXIII	
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assays	are	required.	FXIIID	remains	one	of	the	most	underdiagnosed	
rare	 bleeding	 disorders.10-12	Although	 comprehensive	 guidelines	 for	
FXIIID	 diagnosis	 have	 been	 published	 by	 the	 International	 Society	
on	 Thrombosis	 and	 Haemostasis	 Scientific	 and	 Standardization	
Committee	(ISTH-	SSC),	these	have	not	been	implemented	uniformly	
worldwide	due	to	insufficient	laboratory	assay	resources.13	However,	
they	have	 lead	 to	a	significant	 improvement	 in	diagnostic	efficiency	
in	parts	of	the	world	in	which	they	are	used	for	diagnosis.	Therefore,	
novel	approaches	are	required	for	the	diagnosis	of	FXIIID	to	address	
the	gap	between	expected	prevalence	and	established	diagnoses.
A	report	on	the	Annual	Global	Survey	of	the	worldwide	distribu-
tion	of	rare	bleeding	disorders	by	the	World	Federation	of	Hemophilia	
published	in	October	2015	revealed	1327	patients	with	FXIIID	regis-
tered	from	65	counties.14	This	survey	revealed	that	half	of	available	
data	originated	from	Europe,	underscoring	the	need	for	increased	ef-
forts	to	establish	accurate	diagnosis	and	improve	worldwide	data	col-
lection	systems.	Based	upon	this	survey,	many	developing	countries	
did	not	report	patients	with	FXIIID,	emphasizing	the	difficulty	in	diag-
nosis	in	resource-	poor	settings.	The	data	further	underscore	the	need	
to	improve	diagnostic	tools	and	develop	novel	approaches	to	diagnose	
patients	with	FXIIID.
The	aim	of	this	report	was	to	present	a	comprehensive	and	updated	
overview	of	FXIIID	diagnosis,	including	diagnostic	tools	and	challenges,	
and	 to	propose	 an	 algorithm	 that	may	be	 considered	 to	 improve	di-
agnostic	 efficiency	 and	 prevent	missed	 or	 delayed	 FXIIID	 diagnosis,	
thereby	reducing	morbidity	and	mortality	of	patients	with	this	disease.
2  | RESULTS
2.1 | Assays used to measure FXIII activity
Assays	to	measure	FXIII	activity	are	based	on	the	transglutaminase	re-
action	catalyzed	by	FXIII	after	its	activation,	which	is	described	below.
2.1.1 | Factor XIII activation process
FXIII	is	a	proenzyme,	protransglutaminase,	which	circulates	in	an	inac-
tive	form	as	a	heterotetramer	consisting	of	two	catalytic	A	subunits	
and	two	carrier/protective	B	subunits	(FXIII-	A2B2).
13	FXIII	is	activated	
in	 three	 steps:	 initially,	 the	 activation	 peptide	 A,	 consisting	 of	 37	
amino	acids,	 is	cleaved	from	subunit	A	in	the	presence	of	fibrin	and	
thrombin.	Subsequently,	subunit	B	is	dissociated	from	subunit	A	in	the	
presence	of	calcium	and	fibrin.	Lastly,	in	the	presence	of	calcium,	the	
cleaved	FXIII-	A2	undergoes	conformational	changes	exposing	active-	
site	 cysteine	 residues,	which	 react	with	 fibrin	monomers	 catalyzing	
their	cross-	linking.3,12,15
2.1.2 | Transglutaminase reaction catalyzed by 
activated FXIII
Activated	FXIII	(FXIIIa)	acts	in	the	final	stage	of	coagulation	to	stabilize	
the	fibrin	clot.	In	a	first	step,	the	cysteine	residue	of	activated	subunit	
A	reacts	with	a	glutamine	residue	of	a	gamma	chain	fibrin	molecule,	
forming	a	binary	complex,	a	process	during	which	ammonia	is	released	
(Figure	1A).	 In	 a	 second	 step,	 this	binary	 complex	 can	undergo	 two	
different	subsequent	reactions:	(i)	the	primary	amine	group	of	a	lysine	
residue	from	another	gamma	chain	fibrin	molecule	breaks	the	binary	
complex	thioester	bond	in	a	transglutaminase	reaction	and	reacts	with	
the	glutamine	residue,	forming	a	glutaminyl-	lysyl	bond	(Figure	1B);	(ii)	
a	free	amine	group	reacts	with	the	binary	complex,	resulting	in	an	iso-
peptide	glutamine-	amine	bond	(Figure	1C).	These	reactions,	including	
ammonia	 release,	 transglutaminase	 reaction,	 and	 incorporation	 of	 a	
free	amine	group	into	the	glutamine-	FXIIIa	complex,	result	in	gamma	
chain	fibrin	to	fibrin	dimerization	and	cross-	linking,	and	form	the	fun-
damental	basis	for	laboratory	assays	measuring	FXIII	activity	via	spe-
cific	products	released	during	these	steps.16
In	 addition	 to	 cross-	linking	 gamma	 chain	 fibrin	 molecules,	 acti-
vated	 FXIII	 can	 attach	 the	 fibrinolytic	 inhibitor	 (α2	 antiplasmin)	 to	
alpha	chain	fibrin	molecules	to	prevent	premature	degradation	of	the	
formed	clot	by	fibrinolysis	via	plasmin.10,16
2.2 | Diagnostic tools in congenital FXIII deficiency
Complete	diagnosis	of	FXIIID	is	based	upon	identification	of	character-
istic	symptoms,	a	detailed	patient	history,	including	bleeding	at	birth,	
a	thorough	clinical	evaluation,	and	a	variety	of	specialized	laboratory	
tests.	Umbilical	cord	bleeding	at	birth	is	observed	in	more	than	80%	
of	affected	severely	deficient	cases	and	is	therefore	almost	pathogno-
monic	and	highly	suggestive	of	FXIIID.17	Other	hemorrhages,	such	as	
subcutaneous	bleeding,	which	occurs	in	57%	of	patients	with	FXIIID,	
also	 indicate	 specific	 deficiencies,	 including	 FXIIID.3,6,17,18	 Clinical	
symptoms	may	 also	manifest	 in	 some	 heterozygous	 carriers,	which	
should	prompt	further	diagnostic	 investigation	and	clinical	risk	man-
agement.7,9	Delayed	diagnosis	is	associated	with	increased	morbidity	
and	mortality;	as	such,	timely	diagnosis	of	FXIIID	by	clinical	evaluation,	
patient	and	family	history,	and	laboratory	tools	is	crucial.	A	simple	rule	
with	which	to	approach	laboratory	evaluation	is	to	ensure	that	it	is	flex-
ible,	readily	available,	reliable,	and	accurate.	In	vitro	assays	to	confirm	
diagnosis	include	the	following:	(i)	clot	solubility	test,	(ii)	FXIII	activity	
assay,	(iii)	FXIII	antigen	assay,	(iv)	inhibitor	assay,	and	(v)	molecular	di-
agnosis	and	thromboelastography	(TEG).	TEG	is	currently	not	stand-
ardized	and	therefore	not	further	discussed	in	this	review.	Advantages	
and	disadvantages	of	the	other	assays	are	discussed	below.
2.2.1 | Clot solubility test (CST)
The	first	case	of	FXIIID	described	was	diagnosed	in	1960	using	this	
method.19	Its	sensitivity	to	FXIII	activity	levels	depends	on	fibrinogen	
level,	clotting	(thrombin	and/or	Ca2+),	and	solubilizing	agents	and	their	
concentration	 (2%	acetic	acid,	1%	monochloroacetic	 [MCA]	acid,	or	
5	mol	L−1	urea)	 (Table	1).	As	hypofibrinogenemia	and	dysfibrinogen-
emia	can	cause	false-	positive	results	using	the	5	mol	L−1	urea	solubil-
ity	test,	 functional	assays	should	be	performed	 in	case	of	a	positive	
5	mol	L−1	urea	test	to	rule	out	hypo-	or	dysfibrinogenemia	patients.10 
Hypofibrinogenemia	and	dysfibrinogenemia	can	be	confirmed	or	ex-
cluded	using	thrombin	time,	reptilase	time,	and/or	a	fibrinogen	antigen	
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assay	in	conjunction	with	a	fibrinogen	activity	assay.	High	pepsinogen	
levels,	as	 they	may	occur	 in	patients	with	gastric	diseases	or	a	heli-
cobacter	pylori	 infection,	can	also	lead	to	a	false-	positive	CST	when	
using	acetic	acid-	based	assays.20
The	 advantages	 of	 the	CST	 are	 that	 it	 is	 easy	 to	 perform,	 inex-
pensive,	 and	without	 specific	 instrumentation	 requirements,	 so	 that	
it	 can	 be	 established	 in	 most	 laboratories.	 However,	 disadvantages	
include	a	 lack	of	 standardization	and	 low	sensitivity	 (inability	 to	de-
tect	 mild	 or	 moderate	 deficiency,	 including	 heterozygous	 carriers).	
The	CST	therefore	underestimates	the	number	of	FXIIID	cases,	may	
lead	to	missed	or	delayed	diagnosis,	and	cannot	be	used	for	monitor-
ing	prophylactic	treatment.4,10,13	Although	it	 is	not	recommended	as	
a	 routine	screening	 test	 for	 the	aforementioned	 reasons,	 the	CST	 is	
often	the	first	screening	test	utilized	in	many	coagulation	laboratories	
in	developing	countries	as	well	 as	 in	20%	of	developed	countries.10 
Apart	from	resource	issues,	the	lack	of	regulatory	approval	for	some	
commercially	 available	 quantitative	 assays	may	 present	 a	 barrier	 to	
more	widespread	adoption	and	use.	Therefore,	these	assays	cannot	be	
F IGURE  1 Transglutaminase	reaction	and	assay	principles	for	measurement	of	FXIII	activity.	The	dashed	boxes	indicate	the	products	
measured	with	the	respective	assay
LysineGlutamine
Lysine
Glutamine -C-NH2
O
Cysteine FXIIIaH-S-
NH3
(B)
(A)
(C)
Pepde2H2N-
+
+
Pepde1 -C-N-
O
Pepde2
H
Cysteine FXIIIaH-S-+
Pepde1
Glutamine -C-S-
O
Cysteine FXIIIaPepde1
Glutamine -C-S-
O
Cysteine FXIIIaPepde1
Glutamine -C-S-
O
Cysteine FXIIIaPepde1 + H2N-R
GlutaminePepde1 -C-N-R
O
H
Cysteine+ FXIIIaH-S-
Ammonia release assay
Amine incorporaon assay
Photometric or fluorogenic
transglutaminase acvity 
assays
Clotting agent
Solubilizing 
agent
Sensitivity to 
FXIII levels (%) Comment
CaCl2 Urea <0.5-	5 More	specific	than	acetic	acid-	based	assay
Thrombin Acetic	acid 10 Sensitive	and	rapid,	but	less	specific	than	
urea-	based	assay
CaCl2 Acetic	acid 0-	3 Less	sensitive	than	urea-	based	assay
TABLE  1 Clotting	and	solubilizing	
agents:	important	factors	that	determine	
the	sensitivity	of	the	clot	solubility	test	
[adapted	from2]
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discarded	as	screening	tests,	especially	in	developing	countries	due	to	
the	lack	of	alternative	assays	with	better	sensitivity	to	moderate	and	
mild	deficiency	states;	 for	this	reason,	the	quality	of	the	test	should	
be	optimized	 to	minimize	 the	number	of	patients	with	undiagnosed	
FXIIID.	Although	international	recommendations	or	guidelines	do	not	
exist	 for	 the	use	of	 the	CST,	an	optimized	strategy	may	 include	 the	
utilization	of	two	different	CSTs	with	5	mol	L−1	urea	or	acetic	acid	as	
solubilizing	agents	and	CaCl2	or	thrombin	as	clotting	agents,	respec-
tively,	in	parallel.2	FXIIID	should	be	considered	if	one	of	the	two	CSTs	
is	 abnormal.	The	establishment	of	 a	 local	 cutoff	 solubility	 time	may	
also	be	of	advantage	to	optimize	this	strategy.
2.2.2 | Quantitative assays (functional activity 
assays)
Quantitative	 FXIII	 activity	 assays	 are	 recommended	 as	 first-	line	
screening	tests	whenever	possible.	Three	main	methods	are	used	to	
measure	 FXIII	 activity	 levels,	 all	 currently	 based	 upon	 the	 transglu-
taminase	 reaction	 in	 the	 cross-	linking	 process:	 (i)	 ammonia	 release	
assay,	 (ii)	amine	 incorporation	assay,	and	(iii)	 isopeptidase	assay.13,16 
There	are	challenges	and	limitations	to	each	of	the	quantitative	meth-
ods	used	for	FXIIID	diagnosis,	the	major	disadvantages	being	variation	
in	the	limit	of	quantitation	(<1%-	10%)	and	low	sensitivity.	The	details	
of	these	three	methods,	including	advantages	and	disadvantages,	are	
described	below	and	in	Table	2.2,10,13,16,21,22
•	 The	ammonia	release	assay	is	the	most	common	and	convenient	
method	due	to	the	short	time	required	for	performance	(10	min-
utes).	 It	 measures	 FXIII	 activity	 via	 photometric	 absorbance	 at	
340	nm	wavelength,	which	is	decreased	in	the	presence	of	FXIII	
activity	by	a	glutamate	dehydrogenase-mediated	 indicator	reac-
tion	in	which	one	molecule,	NADH	or	NADPH,	combined	with	one	
molecule	of	ammonia	is	converted	to	NAD+	or	NADP.	Increased	
activity	for	levels	<10%	may	be	observed,	thereby	causing	over-
estimation.3,16	 The	 cause	 of	 this	 increased	 activity	 is	 FXIIIa-
independent	 ammonia	 release,	 which	 adds	 to	 FXIII-dependent	
ammonia	release.	Therefore,	the	use	of	a	plasma	blank	is	required,	
in	which	FXIIIa	is	inhibited	by	1	mmol	L−1	iodoacetamide	and	only	
released	ammonia	not	related	to	FXIIIa	activity	is	measured.	The	
subtraction	of	a	plasma	blank	from	patient	plasma	 is	absolutely	
required	to	avoid	incorrect	results	in	the	low	activity	range	(<5%-
10%),	 and	 its	 application	 ensures	 a	 more	 reliable	 detection	 of	
FXIIID	patients	with	levels	<5%.23	Failure	to	subtract	the	plasma	
blank	may	result	in	serious	clinical	consequences	if	patients	with	
very	 low	FXIII	activity	appear	to	have	acceptable	 levels	and	are	
not	 correctly	 diagnosed	 and	 managed	 accordingly.	 Three	 com-
mercial	ammonia	release	assay	kits	are	currently	available,	some	
of	which	supply	a	reagent	for	measurement	of	a	plasma	blank;	if	a	
plasma	blank	is	not	supplied,	this	should	be	prepared	by	the	local	
laboratory.
•	 In	 the	amine	 incorporation	assay,	 fluorescent,	 radiolabeled,	or	bi-
otinylated	 amines	 covalently	 bound	 to	 a	 glutamine	 residue	 of	 a	
substrate	 are	 measured	 after	 free	 unbound	 amines	 have	 been	
separated	from	the	protein-bound	fraction.	Although	amine	incor-
poration	assays	are	more	sensitive	than	the	ammonia	release	assay,	
they	 are	more	difficult	 to	 standardize,	 have	difficulty	with	 repro-
ducibility,	and	are	time-consuming.	Moreover,	certain	types	of	this	
assay	that	measure	transglutaminase	activity	at	the	initial	stage	of	
FXIII	 activity	 are	 sensitive	 to	 the	 Val34Leu	 FXIII	 polymorphism,	
resulting	 in	falsely	 increased	FXIII	activity	when	present,	whereas	
those	assays	measuring	the	transglutaminase	activity	of	the	com-
pletely	activated	enzyme	are	not	affected.13
•	 The	 isopeptidase	 assay	 is	 based	 on	 the	 isopeptidase	 activity	 of	
FXIIIa	under	certain	conditions,	which	results	in	the	gradual	removal	
of	primary	amines	bound	to	a	glutamine	residue	in	an	oligopeptide.	
This	gradual	release	of	amines	containing	a	quencher	results	in	in-
creased	fluorescence	of	a	peptide	substrate,	which	is	labeled	with	
a	 fluorophore.16	 Although	 overestimation	 does	 not	 occur	 in	 this	
assay,	the	limit	of	quantitation	is	around	5%	normal	FXIII	activity;	
therefore,	it	is	less	sensitive	than	other	FXIII	activity	assays.16
2.2.3 | Immunological assays (FXIII antigen assays)
A	FXIII	 antigen	 assay	 is	 required	 for	 the	 classification	of	FXIII	 defi-
ciency.	 If	FXIII	activity	 is	decreased,	 the	deficiency	subtype,	FXIII-	A	
or	FXIII-	B,	is	determined	using	an	immunological	FXIII	antigen	assay	
to	assure	appropriate	classification	and	treatment.	Several	FXIII	anti-
gen	assays	are	available,	including	immunoassays	to	measure	FXIII-	A,	
FXIII-	B,	 and	 the	FXIII-	A2B2	 complex.	Clearly,	 one	 limitation	 to	 anti-
gen	 assays	 is	 that	 they	may	 fail	 to	 identify	 rare	qualitative	 (type	 II)	
deficiencies,	 in	which	the	FXII-	A	enzyme	 is	present	but	 functionally	
defective.12	 Although	 assays	 for	 the	measurement	 of	 the	 different	
FXIII	subunits	are	available,	some	centers	may	only	use	the	most	fre-
quently	employed	FXIII-	A	ELISA,	thereby	not	complying	with	current	
recommendations	 and	 potentially	 missing	 the	 rarer	 FXIII-	B	 subunit	
deficiency.
Electroimmunoassays	 (EIA),	 radioimmunoassays	 (RIA),	 latex-	
enhanced	 immunoprecipitation	 assays,	 or	 enzyme-	linked	 immuno-
sorbent	assays	(ELISA)	are	four	common	immunoassay	methods;	with	
ELISA	considered	superior	to	other	methods.	Several	types	of	ELISA	
are	 in	 use,	 including	 highly	 sensitive	 chemiluminescence	 FXIII	 anti-
gen	ELISAs	and	R-	ELISA	FXIII	 (Reanal-	ker,	Budapest,	Hungary).3,10,16 
The	FXIII	antigen	ELISA	method	has	a	limit	of	detection	of	0.014	μg/L	
(FXIII-	A),	0.019	μg/L	(FXIII-	B),	and	0.016	μg/L	(FXIII-	A2B2),	laboratory	
imprecision	of	<12%,	and	an	estimated	total	error	of	<25%.24	The	R-	
ELISA	FXIII	method	is	a	one-	step	sandwich	ELISA	with	good	sensitivity	
(as	low	as	0.1%)	and	suitable	for	monitoring	substitution	therapy.16,24 
Other	methods,	 including	EIA	and	RIA,	are	used	 infrequently	due	to	
lower	sensitivity,	laborious	procedures,	or	because	they	may	produce	
artifacts.25
2.2.4 | Inhibitor (autoantibody) assays
Detected	low	factor	activity	can	be	attributed	to	congenital	factor	de-
ficiency	or	development	of	an	autoantibody,	leading	to	autoimmune	
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FXIII	 deficiency;	 these	 cannot	 be	 differentiated	 using	 quantita-
tive	 assays.	 Inhibitor	 assays	 are	 performed	 to	 determine	 whether	
FXIIID	in	a	patient	is	hereditary	or	due	to	formation	of	an	autoanti-
body	recognizing	FXIII.	The	development	of	a	FXIII	autoantibody	 is	
a	 very	 rare	 event,	with	 less	 than	100	 cases	worldwide	 reported	 to	
date26.	Approximately	50%	of	cases	are	 idiopathic,	whereas	under-
lying	diseases	 related	 to	an	 imbalance	of	 the	 immune	system,	 such	
as	 autoimmune	 disorders,	 solid	 neoplasms,	 myeloproliferative	 and	
lymphoproliferative	 diseases,	 prolonged	 drug	 use,	 and	 pregnancy,	
are	also	associated	with	the	development	of	autoantibodies	against	
FXIII.	Autoimmune	FXIII	deficiency	occurs	mainly	in	older	adults	and	
can	 result	 in	drastically	decreased	FXIII	 levels,	with	potentially	 life-	
threatening	 bleeding.	 Clinical	 symptoms	 cover	 a	 large	 range	 from	
common	 multiple	 mucocutaneous	 or	 intramuscular	 bleeds	 to	 life-	
threatening	 internal	hemorrhages.26	Older	adults	with	a	 recent	and	
spontaneous	onset	of	bleeding	symptoms	lacking	previous	bleeding	
symptoms,	 even	 when	 undergoing	 surgery	 or	 invasive	 procedures,	
and	with	no	family	history	of	FXIIID	should	be	considered	and	FXIII	
antigen	and	 inhibitor	assays	performed.	There	are	two	types	of	au-
toantibody:	(i)	neutralizing	autoantibodies	against	FXIII-	A,	which	can	
be	measured	 using	mixing	 studies	 in	which	 FXIII	 activity	 in	 normal	
plasma	is	inhibited	by	a	neutralizing	autoantibody	in	a	mixture	of	pa-
tient	and	normal	plasma,	and	(ii)	non-	neutralizing	inhibitors,	which	are	
determined	using	binding	assays	to	detect	the	binding	of	a	patient’s	
IgG	(IgM)	to	purified	plasma	FXIII	and	purified	FXIII	subunits	in	a	non-
commercially	available	ELISA	by	adding	anti-	human	IgG	or	in	dot	blot	
arrangements.10,13	The	use	of	 an	 inhibitory	 assay	 is	 age-	dependent	
and	not	recommended	for	FXIIID	evaluation	when	diagnosed	at	birth,	
as	 the	development	of	 a	FXIII	 autoantibody	 is	 unlikely	 in	neonates	
or	babies	who	have	not	been	exposed	to	a	FXIII	product.	The	effect	
of	the	presence	of	FXIII	autoantibodies	on	FXIII	activity	and	antigen	
levels	are	summarized	in	Table	3.
2.2.5 | FXIII molecular (genetic) analysis
Molecular	 analysis	 requires	 amplification	 and	 sequencing	of	 FXIII-	A	
and/or	FXIII-	B	genes.	The	A	subunit	gene	is	located	on	chromosome	
6	and	contains	15	exons	and	14	introns.	To	date,	153	mutations	have	
been	reported,	of	which	missense	mutations	occur	in	more	than	half	
of	 cases	 and	 represent	 the	most	 common	 type	of	 genetic	defect.27 
Severe	and	spontaneous	bleeding	episodes	occur	in	both	homozygous	
and	heterozygous	patients,	 the	 latter	more	commonly	under	hemo-
static	stress	situations.7-9
FXIII	subunit	B	deficiency	accounts	for	less	than	5%	of	recognized	
FXIIID	 cases.	The	B	 subunit	 gene	 is	 located	on	 chromosome	1	 and	
contains	 12	 exons	 and	 11	 introns;	 16	 mutations,	 mostly	 missense,	
have	been	reported.28	The	absence	of	FXIII	subunit	B	leads	to	shorter	
plasma	half-	life	of	FXIII	subunit	A.	FXIII	subunit	B	deficiency	causes	
a	less	severe	phenotype	due	to	the	remaining	5%-	10%	FXIII	activity	
present	in	the	plasma.6,27
The	FXIII-A	gene	is	highly	polymorphic,	and	a	number	of	molecular	
variants	have	been	characterized.	FXIII-	specific	activity	in	normal	indi-
viduals	is	related	to	specific	polymorphisms	in	the	FXIII-A	gene.	More	
than	1000	noncoding	polymorphisms	have	been	observed	in	both	FXIII	
subunits.	 Five	 common	 coding	 polymorphisms	 have	 been	 detected	
in	 the	 FXIII-A	 gene	 and	 affect	 either	 FXIII	 activity	 or	 plasma	 level:	
Val34Leu	(the	most	common;	accelerated	FXIII	activation),	Tyr204Phe	
(decreased	FXIII	plasma	level	and	activity),	Pro564Leu	(decreased	FXIII	
plasma	 level	 and	 increased	FXIII	 activity),	Glu651Gln,	 and	Val650IIe	
(low	to	normal	FXIII	activity).27	The	frequency	of	polymorphisms	has	
been	observed	to	be	dependent	on	ethnicity.	The	spectrum	of	com-
mon FXIII-A	gene	mutations	in	a	few	selected	countries,	including	both	
developed	and	developing	countries,	 is	 shown	 in	Table	4.27	 In	 some	
countries,	 molecular	 analysis	 can	 facilitate	 diagnosis	 if	 population-	
specific	 mutations	 are	 known.	 Based	 on	 this	 knowledge,	 genetic	
analysis	 in	some	countries	may	aid	diagnosis,	especially	 in	 less	well-	
equipped	coagulation	 laboratories;	 in	this	circumstance,	after	a	CST,	
targeted	genetic	analysis	could	be	performed	in	reference	laboratories	
prior	to	more	specific	FXIII	activity	and	antigen	assays.	This	strategy	
involves	a	polymerase	chain	reaction-	restriction	fragment	length	poly-
morphism	(PCR-	RFLP)	assay	or	the	sequencing	of	a	short	specific	DNA	
segment	limited	to	one	or	two	exons,	both	of	which	require	knowledge	
of	specific	primers;	this	type	of	testing	requires	 less	than	24	hours.2 
This	strategy	may	be	useful	 in	countries	 in	which	highly	specific	 re-
current	mutations	are	common;	it	will	not	detect	spontaneous	novel	
mutations.	An	example	where	this	strategy	has	been	employed	is	Iran,	
where	 nearly	 one-	third	 of	 all	 patients	 with	 FXIIID	 worldwide	 have	
been	 reported.	 Two	 mutations	 are	 found	 commonly,	 of	 which	 one	
(c.562T>C)	was	detected	in	95%	of	affected	patients.29,30	Using	this	
approach,	identified	FXIIID	cases	increased	more	than	twofold	within	
2	years	 from	2014	 (217	 registered	patients,	 annual	 report	 of	WFH)	
to	2016	(483	patients).29,31	In	addition,	FXIII-	targeted	genetic	analysis	
TABLE  3 FXIII	activity	and	antigen	levels	in	the	presence	of	autoantibody	[adapted	from13]
FXIII- autoantibody Plasma FXIII activity
Plasma FXIII- A2B2 
antigen
Plasma FXIII- A 
antigen
Plasma FXIII- B2 
antigen
Platelet 
FXIII activity
Platelet 
FXIII- A antigen
A
Neutralizing	antibody Severe	decrease	(<3%) NL	or	slight	
decrease
NL	or	slight	
decrease
Decrease	(>30%) NL NL
Non-	neutralizing	antibody Severe	decrease	(FXIII-	A) Severe	decrease Severe	decrease Decrease	(>30%) NL NL
B
Non-	neutralizing	antibody Severe	decrease	(<3%) Severe	decrease Severe	decrease Severe	decrease NL NL
FXIII,	factor	XIII;	FXIII-	A,	factor	XIII	subunit	A;	FXIII-	A2B2,	factor	XIII	A2B2-	heterotetramer;	FXIII-	B2,	factor	XIII	B2-	homodimer;	NL,	normal	level.
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with	 these	 founder	mutations	has	allowed	for	genetic	counseling	of	
relatives	of	affected	patients,	many	of	whom	are	likely	to	be	heterozy-
gous	carriers,	with	an	option	for	antenatal	diagnosis.
3  | DISCUSSION
The	diagnosis	of	FXIIID	represents	a	significant	challenge	and	may	re-
quire	a	variety	of	approaches	based	on	geographic	area	and	laboratory	
facility	availability.	Issues	include	normal	routine	coagulation	screen-
ing	tests,	necessitating	advanced	laboratory	techniques,	which	often	
are	not	available	in	a	considerable	number	of	developing	countries.	As	
a	 result,	FXIIID	 is	one	of	 the	most	underdiagnosed	rare	coagulation	
disorders.10-12	Family	and	patient	history	along	with	clinical	evaluation	
are	important	to	raise	suspicion	and	early	diagnosis;	as	such,	aware-
ness	of	clinical	symptoms	indicative	of	this	disorder	is	paramount	to	
ensure	 timely	diagnosis,	 including	abnormal	umbilical	cord	bleeding,	
delayed	 umbilical	 detachment,	 intracranial	 bleeding	 in	 a	 full-	term	
newborn,	and	subcutaneous	bleeding.	In	addition,	women	with	FXIIID	
experience	a	high	rate	of	miscarriage.32	Heightened	clinical	suspicion	
and	referral	of	suspected	cases	to	comprehensive	hemophilia	centers	
at	an	early	age	is	crucial	to	minimize	delayed	diagnosis	and	increased	
Developing or emerging 
country Developed country
Iran Tunisia Pakistan Finland The netherlands
Mutation(s) Trp187Arg
Arg77His
c.869insC Ser296Arg 
c.2045G>A 
IVS11+1G>A
Arg661X Arg326Gln
Gly262Glu
Val316Phe
TABLE  4 Commonly	reported	FXIII-	A	
gene	mutations	in	different	countries	
[extracted	from27]
F IGURE  2 Algorithm	to	guide	the	
diagnosis	of	FXIII	deficiency.	*Alpha2	
antiplasmin	deficiency	and	other	rare	
deficiencies	should	be	considered	
if	FXIII	assays	negative.	**Without	
capacity	to	perform	quantitative	assays.	
†Performance	of	assay	is	age-	dependent;	
not	recommended	for	neonates.	‡If	
clot	solubility	test	is	normal,	but	clinical	
symptoms	support	FXIIID,	sample	should	
be	sent	to	reference	laboratory	for	FXIII	
activity	measurement.	§Mutation	analysis	
performed	in	countries	with	specific	
common	and	recurrent	mutations.	§§Send	
sample	to	central,	national,	or	international	
reference	laboratory	if	not	locally	available.	
aPTT,	activated	partial	thromboplastin	
time.	PT,	prothrombin	time.	PFT,	platelet	
function	test.	FXIII,	factor	XIII
Patient history Family history
Positive family history or patient history of umbilical cord stump bleeding, delayed umbilical 
detachment, intracranial bleeding, subcutaneous bleeding, any other abnormal bleeding history or 
recurrent miscarriage
Highly suggestive of FXIII 
deficiency*
Routine hemostasis assays:
aPTT, PT, PFT, platelet countAbnormal Normal
Other coagulation or 
platelet function disorders
Clinical evaluation
Well-equipped coagulation laboratory Less well-equipped coagulation 
laboratory**
1. Clot solubility test
(using 2 methods in parallel)
1. FXIII quantitative activity assay as first-
line screening test
2. Plasma FXIII-A2B2
antigen measurement
2. Country-specific 
mutation analysis§§
Abnormal‡
2. FXIII activity and 
antigen assays§§
3. FXIII-A and FXIII-B antigen measurement
4. Autoantibody assay†
6. Molecular genetic analysis
Confirmed FXIII 
deficiency diagnosis 
Decreased
Decreased
Rapid FXIII deficiency 
diagnosis allowing for rapid 
treatment
OR§
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rates	of	morbidity	and	mortality.	False-	positive	platelet	function	tests	
may	contribute	to	missed	or	delayed	diagnosis	of	FXIIID.	Symptoms	
of	 severe	 umbilical	 cord	 bleeding,	 intracranial	 hemorrhage,	 and	 he-
marthrosis	are	unusual	in	patients	with	platelet	function	disorders.17
Specific	 common	 and	 recurrent	mutations	 in	 geographic	 areas	
due	 to	 founder	 effects	 may	 facilitate	 diagnosis	 through	 estab-
lishment	 of	 targeted	 genetic	 testing;	 if	 targeted	 genetic	 tests	 are	
available	 in	 reference	 laboratories,	 diagnosis	 may	 be	 established	
more	 rapidly,	 especially	 if	 specific	 functional	 tests	 are	 not	 readily	
available.	 This	 strategy	 cannot	 be	 implemented	 in	 all	 countries	 if	
causative	mutations	are	not	consistent	or	vary	within	a	country.	For	
example,	mutation	Trp187Arg	exists	almost	exclusively	in	southeast	
Iran,	where	the	largest	global	population	of	patients	with	FXIIID	has	
been	identified;	performing	targeted	genetic	analysis	after	a	positive	
CST	greatly	 improved	identification	of	affected	cases	 in	this	area.2 
In	 geographic	 regions	with	 a	 known	elevated	 incidence	of	 FXIIID,	
and	 particularly	 among	 families	with	 affected	 homozygous	 FXIIID	
individuals,	the	targeted	diagnosis	and	appropriate	management	of	
heterozygous	carriers	may	be	prudent	 in	the	context	of	premarital	
or	family	planning	counseling,	planned	invasive	procedures,	bleed-
ing	symptoms,	miscarriage,	or	menorrhagia.7-9
The	establishment	of	a	national	reference	laboratory	for	analysis	is	
ideal	in	countries	with	less	well-	equipped	local	coagulation	laborato-
ries.	Countries	with	a	wide	variety	of	causative	mutations	do	not	lend	
themselves	to	use	of	targeted	genetic	analysis,	and	hence	confirmation	
of	FXIIID	through	specific	FXIII	activity	assays	in	a	central,	national,	or	
international	 laboratory	is	required.	Access	to	a	reference	laboratory	
that	 can	perform	FXIII	 activity	 assays	 is	 crucial	 for	 the	 diagnosis	 of	
symptomatic	milder	FXIIID	and	heterozygous	carriers,	who	cannot	be	
identified	using	CSTs	alone.	In	such	areas,	the	CST	quality	should	also	
be	optimized	through	use	of	two	simultaneous	different	CST	methods.	
Therefore,	an	algorithm	for	diagnosis	of	FXIIID	reflecting	a	variety	of	
approaches	 based	upon	 local	 coagulation	 laboratory	 availability	 and	
capability	for	FXIII	assays	is	proposed	(Figure	2).
The	 first	 step	 in	 the	 diagnostic	 approach	 to	 FXIIID	 requires	 de-
tailed	patient	and	family	history,	and	a	clinical	evaluation,	with	atten-
tion	to	bleeding	episodes	typical	of	the	disorder.	In	suspected	cases,	
the	proposed	algorithm	may	be	utilized.	There	exist	limitations	to	ex-
isting	quantitative	FXIII	activity	assays,	including	the	most	commonly	
utilized	 ammonia	 release	 assay,	 even	 in	well-	equipped	 laboratories,	
most	specifically	in	the	low	activity	ranges;	the	use	of	a	plasma	blank	
minimizes	this	effect	and	allows	differentiation	of	severe	cases.	Less	
well-	equipped	 laboratories,	without	 the	capacity	 to	perform	quanti-
tative	assays,	may	use	CST	in	conjunction	with	country-	specific	cen-
tralized	 targeted	mutation	analysis	or	FXIII	 activity	measurement	 to	
ensure	 timely	 diagnosis.	Using	 this	 combination	 of	 approaches	may	
result	in	improved	diagnostic	capacity	and	case	identification.
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